Breast Cancer Study With Hemispherx Biopharma's Ampligen(R) Commences
22 août 2011 10h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 22, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) announced that investigators from the Tumor Vaccine Group (TVG) at the University of Washington in Seattle, WA,...